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Aims Automatic daily transmission of data from implantable cardioverter–deﬁbrillators (ICDs) enables the remote moni-
toring of device status and leads function. We report on a 2-year experience with remote monitoring in 40 recipients
of high-voltage ICD leads, prone to fracture and under advisory since October 2007.
Methods
and results
The ICDs were remotely monitored as well as systematically interrogated in the ambulatory department every 3
months. The patients were also seen in case of abnormal lead impedance, or other manifestations consistent with
lead dysfunction. Over a mean follow-up of 22+4 months after ICD implantation, four lead dysfunctions were sus-
pected because of remotely transmitted oversensing of noise artifacts, abrupt rise in pacing impedance, or both. A
lead fracture needing lead replacement was conﬁrmed in three patients (7.5%), two of them before any inappropriate
therapy and one after the delivery of three inappropriate shocks. No lead failure was observed in the remaining 36
patients, either at the time of ambulatory visits or during remote monitoring.
Conclusion Remote monitoring allowed the early and reliable detection of ICD leads failure without requiring any patient
intervention.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
Keywords Telemedicine † Remote monitoring † Lead failure † Implantable cardioverter–deﬁbrillator † Inappropriate shock
Introduction
The lead system is a critical component of all implantable cardio-
verter–deﬁbrillators (ICDs). However, because of their complex
structure, the leads are susceptible to defects and fractures,
1
exposing patients to the potentially fatal risks of inappropriate
therapy, failure to deﬁbrillate, or loss of pacing function.
2–4
Among several lead models that have been under advisory,
5,6 the
latest concerns the Sprint Fidelis high-voltage ICD leads (Medtro-
nic Inc., Minneapolis, MN, USA),
7 which have been withdrawn from
distribution because of a high fracture rate.
8 The prophylactic
extraction of these implanted leads was not recommended,
9
because of the risks of fatal and non-fatal complications.
10,11
Adverse clinical events related to lead fractures may be preceded
by asymptomatic anomalous lead characteristics, such as abnormal
lead impedance, oversensing due to rapid, non-cardiac potentials,
with or without undersensing, or inappropriate increase in pacing
rate.
12–16 A closer follow-up schedule, the use of special software
that can detect abnormal lead function, and speciﬁc ICDs program-
ming to prevent inappropriate therapy were recommended by the
manufacturer and approved by the National Safety Agency in
October 2007 (Table 1) for all recipients of Sprint Fidelis
leads.
9,17 However, the recommended follow-up at 3-month inter-
vals, including measurements of lead impedance, and sensing and
pacing characteristics, was found insufﬁcient.
13,18 Detection
methods embedded in the implanted devices with sound alerts,
12
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of ventricular ﬁbrillation (VF) were tested to prevent inappropriate
therapies, and though helpful, were also imperfect.
19 Given the
unpredictability of lead fractures, a daily remote lead monitoring
system seemed most likely to detect a lead fracture early and mini-
mize the risk of adverse clinical events.
The ECOST trial
The Effectiveness and Cost of ICDs Follow-up Schedule with Tele-
cardiology (ECOST) is an ongoing randomized trial, which com-
pares a strategy of remote monitoring of ICDs with conventional
follow-ups. The ﬁrst aim of this study is to investigate, with a non-
inferiority hypothesis, whether a daily remote monitoring system
has an impact on the number of patients experiencing at least
one serious adverse event (including all-cause mortality, cardiac-
or device-related serious adverse events). Launched in January
2007 and planned to last until mid-2010, ECOST will enrol 400
patients at 45 French medical centres. Patients are enrolled after
a ﬁrst implant, or replacement, of a single or dual chamber ICD,
with Home MonitoringTM (HM) function (Biotronik SE & Co.
KG, Berlin, Germany),
20 for primary or secondary prevention of
sudden cardiac death. No speciﬁc recommendation was made
initially regarding the type of lead to implant. Patients assigned to
HM undergo automatic daily remote monitoring and are seen in
the ambulatory department at yearly intervals, unless an anoma-
lous ICD function or an event of clinical concern is reported by
HM, requiring an ambulatory visit (Figure 1). Patients assigned to
the control group are followed in the ambulatory department at
6-month intervals. The overall follow-up duration is 27 months.
The protocol of ECOST complies with the French law on the
protection of persons undergoing biomedical research (Huriet
law) and was approved by appropriate authorities, including the
legal authority of the French Agency for the Sanitary Safety of
Health Products (AFSSAPS) and ethics committees. The study
complies with the Declaration of Helsinki. Informed consent has
been obtained from the subjects.
Reaction of the ECOST safety committee
to the Sprint Fidelis advisory
Following the recommendations issued by the National Safety
Agency, the Executive, Safety,Serious Adverse Events, and the Elec-
trogram (EGM) Analysis Committees of ECOST met in November
2007 to discuss the follow-up of the recipients of Sprint Fidelis
leadsenrolledinthetrial.Tocomplywiththehealthauthorities’rec-
ommendations, access to HM was offered to all recipients of Sprint
Fidelis lead, regardless of the random study assignment, along with
ambulatoryICDsfollow-upsat3-monthintervals,constitutingapar-
allel registry within the ECOST trial.
...............................................................................................................................................................................
Table 1 October 2007 decisions and recommendations regarding the management of Sprint Fidelis leads
Decisions and recommendations from the manufacturer Additional recommendations from AFSSAPS
Suspension of commercial distribution Reminder to the physicians to inform the lead recipients,i n
compliance with article L.1111-2 of the Public Health Code
Recall of non-implanted leads Schedule an ambulatory visit within a maximum of 3 months,
followed by the 3-month follow-up schedule recommended by the
manufacturer
It would be inappropriate to extract or replace the lead
prophylactically (statement by an independent physician review
committee). This recommendation is not applicable to patients
presenting with special circumstances. The risk associated with an overt
lead fracture must be weighed against the risk associated with extraction
of the lead or its replacement
At each routine follow-up: Verify that the ICD software has been
updated and,forrecipientsof ICDnotmanufactured by Medtronic,verify
that the device includes similar software capable of triggering an alarm in
case of lead fracture.
Follow-ups should include: Speciﬁc device programming and update of
the ICD software in order to increase the likelihood of detecting a lead
fracture and to lower the risk of inappropriate therapy delivery.
AFSSAPS, the legal authority of the French Agency for the Sanitary Safety of Health Products; ICD, implantable cardioverter–deﬁbrillator.
Figure 1 Follow-ups scheduled in the ECOST trial. After a ﬁrst
in-clinic follow-up, 1–3 months after ICD implantation, patients
assigned to Home Monitoring (HM) undergo automatic daily
remote monitoring. They are seen at yearly intervals unless an
anomalous ICD function or an event of clinical concern is
reported by HM. Patients assigned to the control group are
seen in the ambulatory department every 6 months. Additional
ambulatory visits can be requested by the patients or physicians
at any time in both study groups. RANDO ¼ randomization in
a 1:1 ratio.
Remote surveillance of ICD leads 2247Objectives of this analysis
Home Monitoring enables daily automatic transmission of infor-
mation, including leads data.
21,22 How the remote monitoring of
ICDs may be used to improve the quality of care remains uncer-
tain.
23,24 There is a paucity of prospective data supporting the
safety and efﬁcacy of this surveillance technology applied to leads
under advisory.
14,15 This report describes our 2-year observations
with HM in recipients of Sprint Fidelis lead.
Methods
Home monitoring system and remote
event settings
Home Monitoring uses mobile phone links to transmit ICDs data auto-
matically on a daily basis, as well as instantly upon the occurrence of a
potentially clinically relevant event. Variables that are typically moni-
tored include battery status, lead characteristics, arrhythmias detected,
therapies delivered, mean heart rate, per cent ventricular pacing, and
daily patient activity.
20,22 In case of technical ﬂaw or arrhythmia, a
central data processing facility may alert the physician via e-mail or
mobile phone text messaging, and simultaneously post a detailed
report on a secure website.
22,25,26 The event-triggered reports may
include intracardiac EGM with marker channels.
27,28
Following the AFSSAPS warning regarding the Sprint Fidelis lead, the
ECOST Safety Committee recommended modiﬁcations of the stan-
dard ventricular impedance and absence of HM transmission values
that trigger events, in order to increase the sensitivity of ventricular
lead failure detection (Table 2).
Follow-up and data analysis
Besides the systematic scheduled follow-ups at 3-month intervals, the
recipients of Sprint Fidelis leads were seen at unscheduled visits follow-
ing HM-triggered events or upon their request. We examined the con-
tributions and reliability of HM in the early detection of lead failure,
and measured the number of contributory follow-ups, deﬁned as an
ambulatory visit prompting a change in patient management or ICD
reprogramming, or yielding important information communicated to
the patient. The contributions of scheduled and non-scheduled follow-
ups were compared. Absolute values, per cents, means+standard
deviation, median, and lower/upper quartile were computed as appro-
priate. Continuous variables were evaluated with Kolmogorov–
Smirnov test for normal distribution. Data analysis was performed
with SPSS V18.0 software.
Results
Patient population
Between January 2007 and October 2007, when AFSSAPS issued
the warning, 40 patients enrolled in ECOST received the Sprint
Fidelis lead, of whom 22 were assigned to the control and 18 to
the test group. Their mean age was 64+12 years, and 35
(87.5%) were men. The indications for ICD implantation and the
underlying heart disease are related in Table 3. The mean left ven-
tricular ejection fraction was 35+14%. New York Heart Associ-
ation functional class was II or III in 85% of patients; no patients
were in functional class IV.
Follow-up
The mean follow-up after ICD implantation was 22+4 months.
The mean number of follow-up visits after the warning issued by
AFSSAPS was 5.1+1.5, over 17+3 months (median 18; range
8–18), representing 3.8+0.9 visits per patient per year.
In four patients, HM triggered urgent, unscheduled visits, which,
in three patients, conﬁrmed the presence of lead fractures,
prompting their extractions and replacements. No signs of lead
failure were detected at the time of scheduled follow-up visits or
in HM transmissions in the remaining 36 patients.
................................................................................
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Table 3 Indication for implantable cardioverter–
deﬁbrillator implantation and underlying heart disease
in the 40 recipients of Sprint Fidelis leads
Study group (n 5 40)
Indications for ICD implantation
Primary prevention 26 (65%)
Secondary prevention 14 (35%)
Underlying heart disease
Ischaemic heart disease 32 (80%)
Dilated non-ischaemic cardiomyopathy 3 (7.5%)
Genetic disorders 2 (5%)
Others 3 (7.5%)
Values are number and (%) of patients.
...........................................
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Table 2 Recommended settings for the trigger of
Home Monitoring (HM) events for Sprint Fidelis and
other leads
Settings
Triggers Other leads Sprint Fidelis
Lead
Right ventricular impedance ,250 and
.1500 V
,250 and .1000 if
mean
a ≤70 V
,250 and .1500 if
mean
a .700 V
Right atrial impedance ,250 and .1500 V
Shock impedance ,30 and .100 V
SVT, VT1, VT2, or VF ON
30 J shock ineffective ON
Duration of mode switching .75% (18 h)
Mean ventricular heart rate .100 bpm
Elective replacement
indicator
ON
Absence of HM transmission .14 days .5 days
amean, mean chronic impedance; SVT, supraventricular tachycardia; VT,
ventricular tachycardia; VF, ventricular ﬁbrillation.
L. Gue ´don-Moreau et al. 2248Case no. 1: lead fracture with sensing of artifact and no
abnormal change in impedance
Lead fracture was detected 20 months after implantation. The
event was a single episode of ‘non-sustained VF’ reported by
HM. The online recording of EGM (Figure 2) revealed the presence
of noise, without change in ventricular lead impedance (Figure 3).
Lead fracture was conﬁrmed by embedded Holter EGM recorded
3 days later (Figure 4). The lead was replaced 1 week later. This
lead fracture occurred 10 days after the last scheduled ambulatory
follow-up visit, when no lead dysfunction was observed.
Case no. 2: lead fracture with sensing of artifact and
impedance rise
An episode of ‘non-sustained VF’ was reported by HM, 20 months
afterICDimplantation(Figure2).Anincreaseinventricularleadimpe-
dancefrom540to773Vwasobservedontheprecedingday(Figures3
and 4).The patientunderwent urgentICD interrogation,whennoise
artifacts were observed on the EGM channel upon motion of the left
upperextremity.Theleadwasreplaced4dayslater.Thisleadfracture
occurred 3 months after the last scheduled ambulatory follow-up
visit, when no lead dysfunction had been observed.
Case no. 3: lead fracture with sensing of artifacts,
impedance rise, and shocks delivery
A HM event was triggered 15 months after ICD implantation by a
sudden rise in ventricular lead impedance from 600 to 1294 V
(Figures 3 and 4). No abnormality was found during an unscheduled
ambulatory visit on the same day, when the lead impedance was
734 V. However, 5 days later, the patient was admitted to the hos-
pital for immediate lead replacement, after having received three
inappropriate shocks caused by noise artifacts (Figure 2). This
lead fracture occurred 2.5 months after the last scheduled ICD
follow-up, which had showed no sign of lead dysfunction.
Case no. 4: no lead fracture and rise in impedance
>2000 V
A HM event was triggered by a high ventricular lead impedance,
3 months after ICD implantation. A subsequent review of HM data
recorded since device implantation revealed a 1950 V impedance
at the time of discharge of the patient from the hospital, decreasing
to 800 V over the next few days, and increasing up to 1500 V and
brieﬂyspikingover2000 Vinthe3monthsafterdeviceimplantation
(Figure 3). Repeated measurements in the ambulatory department
Figure 2 Home Monitoring (HM) detected VF in the three cases of conﬁrmed lead fractures. The EGM of cases 1–3 were automatically
recorded before the diagnosis of VF (0 s point) and were transmitted with the other HM data. Patients nos 1 and 2 did not receive ICD
shocks since the ‘arrhythmia’ ended before the conﬁrmation phase. Patient no. 3 received three inappropriate shocks. With the devices
used in this study, EGM are recorded for 3 s before VF is detected. FV, ventricular ﬁbrillation; TV, ventricular tachycardia; Vs, sensed ventricular
beats.
Remote surveillance of ICD leads 2249revealed a ventricular capture threshold at 0.6 V/0.5 ms and a lead
impedance at 1344 and 1521 V, without sensing of artifacts. Sub-
sequent daily observations by HM transmissions up to 6 months
after implantation showed a gradual decrease in lead impedance,
which stabilized at 850 V. The lead has remained functional at a
follow-up of 18 months after ICD implantation.
Other follow-ups triggered by Home
Monitoring
Home Monitoring triggered seven other unscheduled ambulatory
visits, of which four contributed clinical information, including
T-wave oversensing in one, inappropriate shock caused by a supra-
ventricular tachyarrhythmia in one, and non-sustained ventricular
Figure 3 Variations in ventricular lead impedance in the four cases described in the text, compared with the mean impedance (+ SD) in the
remaining 36 patients (light blue area in background). Among the three patients with conﬁrmed lead fractures, an abnormal rise in impedance
was observed in two (cases 2 and 3). In case no. 4, an abnormal impedance was observed during the ﬁrst 6 months after ICD implantation,
without other signs of lead dysfunction. The impedance values were integrated in the Home Monitoring data and triggered an event when
they exceeded pre-selected values.
Figure 4 Summaries of clinical cases. Dates are shown in dd/mm/yy format. Red print indicates abnormalities detected by HM, conﬁrmed at
subsequent ambulatory visits, and lead replacement times. Light red areas indicate time intervals between lead fracture diagnosis and replace-
ment procedures (days at risk). AFSSAPS, the legal authority of the French Agency for the Sanitary Safety of Health Products; HM, Home Moni-
toring; ICD, implantable cardioverter–deﬁbrillator; ImpV, ventricular lead impedance.
L. Gue ´don-Moreau et al. 2250tachycardia and VF in one patient each. In three other patients, HM
was triggered by (i) three episodes of ventricular arrhythmia, (ii) a
rise in atrial impedance, and (iii) a mean daily heart rate
.110 bpm, respectively. Including case no. 4, 4 out of 11 unsched-
uled ambulatory follow-up visits (36%) prompted by HM were
classiﬁed as non-contributory.
Contributions of scheduled follow-ups
Out of 198 scheduled follow-ups, 178 (89.8%) were classiﬁed as
non-contributory. A change in ICD programming, the disclosure
to the patient of the Sprint Fidelis advisory information, as rec-
ommended by the health authorities, or both, occurred during
16 ambulatory follow-up visits. Changes in medical management,
patient reassurance, or both occurred for atrial ﬁbrillation, pulse
generator pocket infection, near syncope, and phantom shocks in
one patient each. Table 4 summarizes the contributions of sched-
uled and unscheduled follow-up visits. The contributions of
unscheduled follow-ups triggered by HM in 7 out of 11 cases
(63%) were considerably greater than in 20 out of 198 scheduled
follow-up visits (10%).
Discussion
By accurately detecting three lead fractures during this study, HM
made important contributions to the follow-up of ICD leads under
advisory,incontrasttotheabsenceofusefulinformationcontributed
by the systematically scheduled ambulatory surveillance of ICDs. In a
study by Hauser et al.,
29 no lead dysfunction was detected among six
recipientsofSprintFidelisleads,followedat4-monthintervals,during
ambulatory visits, which took place between 2 weeks and 3 months
before the diagnosis of lead fractures. These six patients, who were
not under HM, received a total of 57 inappropriate shocks. While
Theuns et al.
25 detected four lead failures in 146 patients (2.7%)
under HM over a mean follow-up of 22 months, we detected,
during a similar observation period, three lead fractures among 40
patients (7.5%), highlighting the particularly important contributions
made by HM in recipients of leads under advisory.
Lead dysfunction is a major concern in ICD recipients, whether it
is due to a systematic manufacturing defect, or to random failure or
dislodgement. A recent study in nearly 1000 recipients of various
ICD lead models between 1992 and 2005 reported failure rates of
15% at 5, and 40% at 8 years, accelerating over time.
1,24 Lead
dysfunction must be detected early in order to prevent major
adverseclinicalevents,includingpotentiallyfatalfailuretodeﬁbrillate
or pace, or deliveryofinappropriateshocks.
2–4 This early detection
has relied on ambulatory visits, the frequency of which cannot be
optimal. Moreover, frequent visits lower the patients’ quality of
life, and are costly and time-consuming. An ideal early detection
strategy needs no patient intervention, particularly since some
patients cannot hear the alarms that should warn them of possible
ICD dysfunctions.
12,18 In a retrospective study, Spencker et al.
16
found that fewer ICD shocks were delivered to patients monitored
remotely than to patients followed in ambulatory departments,
before undergoing replacements of dysfunctional leads.
Home Monitoring allows the detection of initially intermittent
dysfunctions, as shown by the three cases in this study. Spencker
et al.
16 found that in up to 90% of patients presenting with lead
failure, the ﬁrst inappropriate shock was preceded by non-
sustained noise artifacts detected as VF. Home Monitoring also
enables to focus on patients who require particularly close atten-
tion, and plan provocative manoeuvres to be performed during
ambulatory visits when a lead fracture is suspected. The diagnosis
of lead fracture may be challenging and cannot solely be based on
an impedance increase, as illustrated by our case no. 4. On the
other hand, daily measurements of lead impedance do not identify
all lead failures.
12,18 New lead-integrity algorithms can alert the
patients, physicians, or both, of noise oversensing or abnormal
impedance.
12,13 These algorithms, which may increase the
number of intervals triggering the detection of VF, are the ﬁrst
kind of ICDs monitoring function that prompts real-time changes
in VF detection criteria to reduce the risk of inappropriate
shocks.
13 Because the rate of false positive detections of lead frac-
ture ranges between 21 and 35%,
13 EGM need to be veriﬁed,
which can easily be accomplished with HM.
This study illustrates different presentations of lead fracture,
including non-sustained episodes of ventricular tachycardia or VF,
and impedance increase. However, the diagnosis might also be sus-
pected from other signals, such as an increase percent pacing,
which suggests undersensing, or the presence of PVC in the coun-
ters, suggesting oversensing. The suddenness of these signals and
their lack of clinical explanation are consistent with lead failure.
In contrast to ambulatory visits, HM allows the immediate detec-
tion of these signals.
All links in the data transmission chain, including triage,
interpretation, and clinical management of the data must be in
place for the HM system to function properly. The assistance
from the service centre in ensuring the continuity of HM trans-
missions was of great importance. The physician was automatically
alerted when breaks in HM transmissions exceeded 5 days.
Limitation of the study
This study is limited by its observational design. The broader
contributions of HM need to be conﬁrmed by the randomized
ECOST trial.
Conclusions
Over a mean follow-up of 22+4 months after implantation, the
failure rate of the Sprint Fidelis lead in our registry was 7.5%.
...........................................................
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Table 4 Contributions of follow-ups in the 40
recipients of Sprint Fidelis leads
Follow-ups
Contributory Non-contributory Total
Scheduled 20 178 198 (94.8)
Triggered
by HM
7 4 11 (5.2)
Total 27 (12.9) 182 (87.1) 209 (100)
Values are numbers (%) of observations.
HM, Home Monitoring.
Remote surveillance of ICD leads 2251Home Monitoring allowed the early and reliable detection of three
lead fractures, manifest by sensing of noise artefact, abrupt rise in
pacing impedance, or both, without requiring the intervention of
patients in the diagnosis or decision-making process.
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